GH Research PLC's Clinical Progress Updates: A Look at the Company's Future in Psychedelic Medicine

GH Research PLC (GHRS) is advancing efforts to develop psychedelic medicines for depression, bipolar II disorder, and other psychiatric and neurological disorders. The company's flagship drug candidate GH001 targets treatment-resistant depression, bipolar II disorder, and postpartum depression. Guggenheim boosted its price target on GHRS to $34 from $29, citing 2025 financial results and clinical progress updates.